PT1441705E - Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos - Google Patents

Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos Download PDF

Info

Publication number
PT1441705E
PT1441705E PT2787578T PT02787578T PT1441705E PT 1441705 E PT1441705 E PT 1441705E PT 2787578 T PT2787578 T PT 2787578T PT 02787578 T PT02787578 T PT 02787578T PT 1441705 E PT1441705 E PT 1441705E
Authority
PT
Portugal
Prior art keywords
foodstuffs
prompt
excipients
stabilized
modified
Prior art date
Application number
PT2787578T
Other languages
English (en)
Inventor
Maria Gabriella Massironi
Original Assignee
Farmatron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmatron Ltd filed Critical Farmatron Ltd
Publication of PT1441705E publication Critical patent/PT1441705E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT2787578T 2001-11-09 2002-11-06 Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos PT1441705E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI002366A ITMI20012366A1 (it) 2001-11-09 2001-11-09 Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

Publications (1)

Publication Number Publication Date
PT1441705E true PT1441705E (pt) 2014-10-20

Family

ID=11448588

Family Applications (1)

Application Number Title Priority Date Filing Date
PT2787578T PT1441705E (pt) 2001-11-09 2002-11-06 Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos

Country Status (11)

Country Link
US (1) US20050037068A1 (pt)
EP (1) EP1441705B1 (pt)
JP (1) JP2005508982A (pt)
AU (1) AU2002351850B2 (pt)
CA (1) CA2466529C (pt)
CY (1) CY1115707T1 (pt)
DK (1) DK1441705T3 (pt)
ES (1) ES2515790T3 (pt)
IT (1) ITMI20012366A1 (pt)
PT (1) PT1441705E (pt)
WO (1) WO2003039521A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
WO2004069180A2 (en) * 2003-01-31 2004-08-19 Smithkline Beecham Corporation Solid dispersion compositions
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20060134212A1 (en) * 2004-09-02 2006-06-22 Forest Laboratories, Inc. Lercanidipine immediate release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
KR101292573B1 (ko) 2005-11-11 2013-08-12 모치다 세이야쿠 가부시키가이샤 젤리 조성물
GB0524961D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
HUE056937T2 (hu) 2006-02-03 2022-04-28 Opko Renal Llc A D-vitamin elégtelenség és hiány kezelése 25-hidroxivitamin D2-vel és 25-hidroxivitamin D3-mal
PT2679228T (pt) 2006-06-21 2018-04-16 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2008134523A1 (en) 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
KR101959952B1 (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009066299A2 (en) * 2007-11-23 2009-05-28 Rappaport Family Institute For Research Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
WO2009124210A1 (en) 2008-04-02 2009-10-08 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
WO2011121989A1 (ja) * 2010-03-29 2011-10-06 株式会社カネカ 被覆用油脂組成物及びそれを用いた粒子状組成物
CN102939081A (zh) 2010-04-19 2013-02-20 Qlt股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
CN102552923A (zh) * 2012-01-31 2012-07-11 辽宁思百得医药科技有限公司 包含左卡尼汀和辅酶q10的药物组合物及其制备方法
NZ629267A (en) 2012-03-01 2016-11-25 Quadra Logic Tech Inc Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
KR101710441B1 (ko) * 2015-12-28 2017-02-28 신풍제약주식회사 안정성 및 용출성이 향상된 정제
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6112632A (ja) * 1984-06-27 1986-01-21 Eisai Co Ltd 脂溶性薬剤含有組成物
NL8701335A (nl) * 1986-06-21 1988-01-18 Sandoz Ag Orale farmaceutische preparaten.
LU87416A1 (fr) * 1988-12-29 1990-07-10 Cird Microgranules charges en une substance active,constitues essentiellement d'un triglyceride d'acides gras satures et leur utilisation par voie topique dans le domaine therapeutique
TW209174B (pt) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5800834A (en) * 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
BR9815548A (pt) * 1997-07-31 2000-11-07 Kos Pharma Inc Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição
JPH11152220A (ja) * 1997-11-19 1999-06-08 Daiichi Yakuhin Kogyo Kk 脂溶性薬物を含有した丸剤の製造方法
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
FR2785198B1 (fr) * 1998-10-30 2002-02-22 Rhodia Chimie Sa Granules redispersables dans l'eau comprenant une matiere active sous forme liquide
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE251449T1 (de) * 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
KR20020038591A (ko) * 1999-06-18 2002-05-23 오노다 마사요시 경구용 의약 조성물
DE19954923A1 (de) * 1999-11-16 2001-05-17 Bitec Gmbh Verfahren zur Herstellung von gereinigten Pulvern sowie danach erhältliche Pulver
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
EP1116515A3 (en) * 2000-01-11 2002-08-21 Givaudan SA Encapsulated liquid

Also Published As

Publication number Publication date
CA2466529C (en) 2012-07-10
ITMI20012366A1 (it) 2003-05-09
EP1441705B1 (en) 2014-09-03
DK1441705T3 (da) 2014-11-03
US20050037068A1 (en) 2005-02-17
AU2002351850B2 (en) 2008-01-24
EP1441705A1 (en) 2004-08-04
ES2515790T3 (es) 2014-10-30
CY1115707T1 (el) 2017-01-25
JP2005508982A (ja) 2005-04-07
WO2003039521A1 (en) 2003-05-15
CA2466529A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
PT1441705E (pt) Sistemas terapêuticos sólidos, estabilizados, de libertação rápida e/ou modificada para a administração oral de princípios ativos, excipientes ou produtos alimentares líquidos
IL196301A0 (en) Medicament for the treatment of hapatitis c
MXPA03010007A (es) USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA.
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
HUP0500795A3 (en) Gastric retention controlled drug delivery system
MXPA03007215A (es) Formulaciones farmaceuticas.
MXPA03006884A (es) Formulacion farmaceutica.
HUP0204015A3 (en) Devices for the delivery of drugs having antiprogestinic properties
HK1062151A1 (en) Cutaneous administration system
AU2002342050A1 (en) Anesthesia drug monitor
GB0117618D0 (en) Pharmaceutical dosage form
GB0117619D0 (en) Pharmaceutical dosage form
EP1406493A4 (en) ADMINISTRATION OF MEDIUM BY THE PEPT-2 TRANSPORTER
GB0127832D0 (en) Method for the preparation of pharmaceutical nanosuspensions
GB0105893D0 (en) Pharmaceutically active compounds
GB0107751D0 (en) Pharmaceutically active compounds
GB0106631D0 (en) Pharmaceutically active compounds
AU2001232053A1 (en) System for the extracorporeal treatment of blood
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
GB0212790D0 (en) Medicament for the treatment of diabetes
MXPA03010919A (es) Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor.
GB0201607D0 (en) Formulation for the administration of medicinal substances
ZA200306383B (en) Pharmaceutical formulation comprising bicalutamide.
GB0102725D0 (en) Medical delivery system
ZA200402731B (en) Pharmaceutical formulation.